Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVALENT biomarker study of valemetostat in relapsed or refractory peripheral T-cell lymphoma
jRCT1030260509Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valemetostat in peripheral T-cell lymphoma (PTCL), sponsored by National Cancer Institute. Primary endpoint: Association between genomic biomarkers and overall response rate. Started Oct 2026; status: recruiting.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT1030260509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030260509.